|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In HCV<sup>+</sup>(F4) individuals, nearly all CD8<sup>+</sup> T-cell subsets had an elevated proportion of perforin<sup>+</sup> cells while naïve cells had increased proportions of IFN-γ<sup>+</sup> and CD107<sup>+</sup> cells.
|
31456810 |
2019 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 346 chronic hepatitis C (CHC) patients who finished the 48-week pegylated interferon-alpha and ribavirin (PEG IFN-α/RBV) treatment were enrolled in this study.
|
29654010 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
|
29753376 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, the main treatment of CH-C should be direct acting antivirals (DAAs) without Peg-IFN.Peg-IFN is a strong immune-modulator.
|
28293078 |
2017 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
DAAs with or without IFN and RBV in the standard recommended 12 or 24-week treatment regimens are effective, well tolerated, and may be safely extended to elderly patients infected with chronic hepatitis C.
|
28346233 |
2017 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 192 patients with chronic hepatitis C who were treated with simeprevir with Peg-IFN plus ribavirin were analyzed.
|
26223482 |
2016 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Markov model simulated chronic hepatitis C (CHC) treatment interventions with IFN-based and IFN-free regimens at stage of fibrosis ≥F3, ≥F2 or regardless of fibrosis stage, and treatment either with the least or the most expensive combination.
|
27144512 |
2016 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After multivariate analyses the independent positive predictors for SVR after treatment for chronic hepatitis C with Peg-IFN and RBV were: absence of an AIDS-defining illness (p=0.001), HCV viral load lower than 600,000IU/mL at the onset of treatment (p=0.003), higher liver enzyme levels (p=0.039) at baseline, infection with genotypes 2 or 3 (p=0.003), and no transient treatment interruption (p=0.001).
|
25181403 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatic steatosis is a risk factor for both liver disease progression and an impaired response to interferon alpha (IFN-α)-based combination therapy in chronic hepatitis C virus (HCV) infection.
|
25961570 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.
|
25970604 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytopenia during interferon-based (IFN-based) therapy for chronic hepatitis C (CHC) often necessitates reduction of doses of drugs and premature withdrawal from therapy resulting in poor response to treatment.
|
25515861 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
|
26699619 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) near IL28B (IFNλ3) are strongly associated with treatment response to IFNα therapy in chronic hepatitis C (CHC) patients.
|
25611696 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study tested whether differential expression of an important ISG with antiviral properties, tripartite motif 22 (TRIM22), correlates with a response to Peg-IFNα-2a/RBV combination therapy in treatment-naive patients with chronic hepatitis C. A total of 32 patients with chronic hepatitis C were enrolled in this study and received standard Peg-IFNα-2a/RBV combination therapy.
|
24889558 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
|
24929144 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies.
|
24752298 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The occurrence of anti-IFN antibodies is associated with non-response to PEG-IFN in chronic hepatitis C. This study investigated the association between anti-IFN antibodies and response to PEG-IFN in CHB.
|
24296674 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is concluded that the combination of ARFI at cut off of 1.4 m/sec and IL28B may be useful for patients with chronic hepatitis C with genotype 1 treated with peg-IFN/ribavirin combination therapy.
|
24338811 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A reduction of miR-122 expression has been suggested to be associated with responsiveness to IFN-based therapy in patients with chronic hepatitis C. Several independent genome-wide association studies reported a strong association between IFNL3 polymorphism and responsiveness to IFN-based therapy.
|
24672032 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
|
24777626 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Randomized clinical trials and non-randomized clinical studies comparing PEG-IFN-α2a with PEG-IFN-α2b in association with ribavirin in adult patients with chronic hepatitis C were included.
|
23436591 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine the SVR rate in patients ≥ 60 years with genotype 1 chronic hepatitis C treated with Peg-IFN and ribavirin, and to identify risk factors related to treatment response in this specific group of patients.Material and methods.
|
23619255 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).
|
23627926 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
VDR gene polymorphisms are independently related to the response to Peg-IFN+RBV therapy in chronic hepatitis C and could be used as complementary biomarkers of response when included in a prediction algorithm in association with demographic, virologic, biochemical and genetic traits.
|
24073221 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Treatment of genotype 1 naïve chronic hepatitis C with PEG-IFN and ribavirin (RBV) for 48 weeks results in SVR in approximately 40% of patients.
|
23199504 |
2012 |